ENSG00000082898 |
XPO1 |
chronic lymphocytic leukemia |
missense_variant |
3.943% (96/2435) |
11 entries |
ENSG00000082898 |
XPO1 |
Hodgkins lymphoma |
missense_variant |
17.39% (12/69) |
1 entry |
ENSG00000082898 |
XPO1 |
colorectal adenocarcinoma |
missense_variant |
3.571% (43/1204) |
3 entries |
ENSG00000082898 |
XPO1 |
colorectal adenocarcinoma |
sequence_alteration |
3.571% (43/1204) |
1 entry |
ENSG00000082898 |
XPO1 |
cecum adenocarcinoma |
missense_variant |
1.487% (4/269) |
1 entry |
ENSG00000082898 |
XPO1 |
squamous cell lung carcinoma |
missense_variant |
0.5365% (5/932) |
1 entry |
ENSG00000082898 |
XPO1 |
oral squamous cell carcinoma |
missense_variant |
1.527% (4/262) |
3 entries |
ENSG00000082898 |
XPO1 |
bladder transitional cell carcinoma |
missense_variant |
1.307% (6/459) |
2 entries |
ENSG00000082898 |
XPO1 |
prostate carcinoma |
missense_variant |
2.113% (9/426) |
2 entries |
ENSG00000082898 |
XPO1 |
gastric adenocarcinoma |
missense_variant |
1.737% (16/921) |
2 entries |
ENSG00000082898 |
XPO1 |
pancreatic ductal adenocarcinoma |
missense_variant |
2.317% (39/1683) |
2 entries |
ENSG00000082898 |
XPO1 |
hepatocellular carcinoma |
sequence_alteration |
1.016% (10/984) |
1 entry |
ENSG00000082898 |
XPO1 |
colon adenocarcinoma |
missense_variant |
1.323% (17/1285) |
6 entries |
ENSG00000082898 |
XPO1 |
lung adenocarcinoma |
stop_gained |
0.9456% (24/2538) |
2 entries |
ENSG00000082898 |
XPO1 |
prostate adenocarcinoma |
missense_variant |
1.762% (38/2157) |
4 entries |
ENSG00000082898 |
XPO1 |
brain glioblastoma |
missense_variant |
0.4946% (6/1213) |
2 entries |
ENSG00000082898 |
XPO1 |
prostate adenocarcinoma |
sequence_alteration |
1.762% (38/2157) |
1 entry |
ENSG00000082898 |
XPO1 |
gastric adenocarcinoma |
sequence_alteration |
1.737% (16/921) |
2 entries |
ENSG00000082898 |
XPO1 |
gastric intestinal type adenocarcinoma |
missense_variant |
2.353% (2/85) |
1 entry |
ENSG00000082898 |
XPO1 |
bile duct adenocarcinoma |
missense_variant |
0.7712% (3/389) |
1 entry |
ENSG00000082898 |
XPO1 |
prostate carcinoma |
sequence_alteration |
2.113% (9/426) |
1 entry |
ENSG00000082898 |
XPO1 |
Endometrial Endometrioid Adenocarcinoma |
missense_variant |
3.082% (20/649) |
2 entries |
ENSG00000082898 |
XPO1 |
female breast carcinoma |
missense_variant |
1.5% (6/400) |
3 entries |
ENSG00000082898 |
XPO1 |
melanoma |
missense_variant |
2.759% (4/145) |
2 entries |
ENSG00000082898 |
XPO1 |
breast ductal adenocarcinoma |
missense_variant |
2.814% (45/1599) |
1 entry |
ENSG00000082898 |
XPO1 |
esophageal squamous cell carcinoma |
missense_variant |
0.8772% (6/684) |
4 entries |
ENSG00000082898 |
XPO1 |
basal cell carcinoma |
missense_variant |
5.882% (4/68) |
2 entries |
ENSG00000082898 |
XPO1 |
prostate adenocarcinoma |
frameshift_variant |
1.762% (38/2157) |
1 entry |
ENSG00000082898 |
XPO1 |
lung adenocarcinoma |
missense_variant |
0.9456% (24/2538) |
3 entries |
ENSG00000082898 |
XPO1 |
papillary renal cell carcinoma |
missense_variant |
0.8174% (3/367) |
1 entry |
ENSG00000082898 |
XPO1 |
hairy cell leukemia |
missense_variant |
3.636% (2/55) |
2 entries |
ENSG00000082898 |
XPO1 |
hemangioblastoma |
sequence_alteration |
11.43% (4/35) |
1 entry |
ENSG00000082898 |
XPO1 |
Merkel cell skin cancer |
missense_variant |
3.226% (3/93) |
3 entries |
ENSG00000082898 |
XPO1 |
female breast carcinoma |
sequence_alteration |
1.5% (6/400) |
1 entry |
ENSG00000082898 |
XPO1 |
pancreatic ductal adenocarcinoma |
frameshift_variant |
2.317% (39/1683) |
1 entry |
ENSG00000082898 |
XPO1 |
rectal adenocarcinoma |
missense_variant |
1.28% (7/547) |
2 entries |
ENSG00000082898 |
XPO1 |
colorectal adenocarcinoma |
stop_gained |
3.571% (43/1204) |
1 entry |
ENSG00000082898 |
XPO1 |
myelodysplastic syndrome |
missense_variant |
4.054% (3/74) |
2 entries |
ENSG00000082898 |
XPO1 |
clear cell renal carcinoma |
missense_variant |
0.7204% (11/1527) |
1 entry |
ENSG00000082898 |
XPO1 |
urothelial carcinoma |
missense_variant |
5.814% (5/86) |
1 entry |
ENSG00000082898 |
XPO1 |
T-cell acute lymphoblastic leukemia |
missense_variant |
0.5042% (3/595) |
1 entry |
ENSG00000082898 |
XPO1 |
clear cell renal carcinoma |
sequence_alteration |
0.7204% (11/1527) |
1 entry |
ENSG00000082898 |
XPO1 |
diffuse large B-cell lymphoma |
missense_variant |
2.237% (10/447) |
5 entries |
ENSG00000082898 |
XPO1 |
breast ductal adenocarcinoma |
sequence_alteration |
2.814% (45/1599) |
1 entry |
ENSG00000082898 |
XPO1 |
skin melanoma |
missense_variant |
1.121% (13/1160) |
3 entries |
ENSG00000082898 |
XPO1 |
hepatocellular carcinoma |
missense_variant |
1.016% (10/984) |
1 entry |
ENSG00000082898 |
XPO1 |
breast carcinoma |
missense_variant |
0.9296% (14/1506) |
2 entries |
ENSG00000082898 |
XPO1 |
small cell lung carcinoma |
missense_variant |
0.6803% (3/441) |
1 entry |
ENSG00000082898 |
XPO1 |
Invasive Breast Carcinoma |
missense_variant |
4.255% (2/47) |
1 entry |
ENSG00000082898 |
XPO1 |
Kidney Oncocytoma |
sequence_alteration |
2.778% (1/36) |
1 entry |
ENSG00000082898 |
XPO1 |
Brain Stem Glioblastoma |
sequence_alteration |
3.571% (2/56) |
1 entry |
ENSG00000082898 |
XPO1 |
esophageal squamous cell carcinoma |
sequence_alteration |
0.8772% (6/684) |
1 entry |
ENSG00000082898 |
XPO1 |
anaplastic astrocytoma |
sequence_alteration |
0.7634% (1/131) |
1 entry |
ENSG00000082898 |
XPO1 |
pancreatic neuroendocrine tumor |
missense_variant |
3.814% (9/236) |
1 entry |
ENSG00000082898 |
XPO1 |
B-cell acute lymphoblastic leukemia |
sequence_alteration |
1.802% (2/111) |
1 entry |
ENSG00000082898 |
XPO1 |
undifferentiated pleomorphic sarcoma |
missense_variant |
1.613% (1/62) |
1 entry |
ENSG00000082898 |
XPO1 |
esophageal adenocarcinoma |
missense_variant |
3.108% (17/547) |
1 entry |
ENSG00000082898 |
XPO1 |
metaplastic breast carcinoma |
missense_variant |
1.667% (1/60) |
1 entry |
ENSG00000082898 |
XPO1 |
nasopharyngeal squamous cell carcinoma |
missense_variant |
0.5556% (1/180) |
1 entry |
ENSG00000082898 |
XPO1 |
vulvar intraepithelial neoplasia |
frameshift_variant |
9.091% (1/11) |
1 entry |
ENSG00000082898 |
XPO1 |
lobular breast carcinoma |
missense_variant |
1.702% (4/235) |
1 entry |
ENSG00000082898 |
XPO1 |
lobular breast carcinoma |
frameshift_variant |
1.702% (4/235) |
1 entry |
ENSG00000082898 |
XPO1 |
Endometrial Clear Cell Adenocarcinoma |
missense_variant |
3.704% (1/27) |
1 entry |
ENSG00000082898 |
XPO1 |
marginal zone B-cell lymphoma |
missense_variant |
3.333% (1/30) |
1 entry |
ENSG00000082898 |
XPO1 |
gastric adenocarcinoma |
frameshift_variant |
1.737% (16/921) |
1 entry |
ENSG00000082898 |
XPO1 |
colon adenocarcinoma |
frameshift_variant |
1.323% (17/1285) |
1 entry |
ENSG00000082898 |
XPO1 |
brain glioblastoma |
sequence_alteration |
0.4946% (6/1213) |
1 entry |
ENSG00000082898 |
XPO1 |
laryngeal squamous cell carcinoma |
missense_variant |
2.439% (1/41) |
1 entry |
ENSG00000082898 |
XPO1 |
Mast Cell Neoplasm |
missense_variant |
25.0% (1/4) |
1 entry |
ENSG00000082898 |
XPO1 |
Uterine Carcinosarcoma |
missense_variant |
4.054% (6/148) |
1 entry |
ENSG00000082898 |
XPO1 |
B-cell acute lymphoblastic leukemia |
missense_variant |
1.802% (2/111) |
1 entry |
ENSG00000082898 |
XPO1 |
Gallbladder Adenocarcinoma |
missense_variant |
0.7194% (1/139) |
1 entry |
ENSG00000082898 |
XPO1 |
rectal adenocarcinoma |
sequence_alteration |
1.28% (7/547) |
1 entry |
ENSG00000082898 |
XPO1 |
lung adenocarcinoma |
sequence_alteration |
0.9456% (24/2538) |
1 entry |
ENSG00000082898 |
XPO1 |
skin melanoma |
stop_gained |
1.121% (13/1160) |
1 entry |
ENSG00000082898 |
XPO1 |
papillary thyroid carcinoma |
stop_gained |
0.409% (2/489) |
1 entry |
ENSG00000082898 |
XPO1 |
solitary fibrous tumor |
missense_variant |
3.448% (1/29) |
1 entry |
ENSG00000082898 |
XPO1 |
papillary thyroid carcinoma |
missense_variant |
0.409% (2/489) |
1 entry |
ENSG00000082898 |
XPO1 |
leiomyosarcoma |
missense_variant |
1.0% (1/100) |
1 entry |
ENSG00000082898 |
XPO1 |
lung adenocarcinoma |
frameshift_variant |
0.9456% (24/2538) |
1 entry |
ENSG00000082898 |
XPO1 |
pancreatic ductal adenocarcinoma |
stop_gained |
2.317% (39/1683) |
1 entry |
ENSG00000082898 |
XPO1 |
lobular breast carcinoma |
stop_gained |
1.702% (4/235) |
1 entry |
ENSG00000082898 |
XPO1 |
ovarian serous adenocarcinoma |
missense_variant |
0.1193% (1/838) |
1 entry |
ENSG00000082898 |
XPO1 |
small cell lung carcinoma |
sequence_alteration |
0.6803% (3/441) |
1 entry |
ENSG00000082898 |
XPO1 |
adrenal cortex carcinoma |
missense_variant |
0.5291% (1/189) |
1 entry |
ENSG00000082898 |
XPO1 |
gastric adenocarcinoma |
stop_gained |
1.737% (16/921) |
1 entry |
ENSG00000082898 |
XPO1 |
Mixed Lobular and Ductal Breast Carcinoma |
missense_variant |
1.562% (1/64) |
1 entry |
ENSG00000082898 |
XPO1 |
squamous cell lung carcinoma |
stop_gained |
0.5365% (5/932) |
1 entry |
ENSG00000082898 |
XPO1 |
T-cell acute lymphoblastic leukemia |
amino_acid_insertion |
0.5042% (3/595) |
1 entry |
ENSG00000082898 |
XPO1 |
colon adenocarcinoma |
sequence_alteration |
1.323% (17/1285) |
1 entry |
ENSG00000082898 |
XPO1 |
Thyroid Gland Undifferentiated (Anaplastic) Carcinoma |
missense_variant |
0.3802% (1/263) |
1 entry |
ENSG00000082898 |
XPO1 |
esophageal squamous cell carcinoma |
stop_gained |
0.8772% (6/684) |
1 entry |
ENSG00000082898 |
XPO1 |
gastric adenocarcinoma |
conservative_inframe_deletion |
1.737% (16/921) |
1 entry |
ENSG00000082898 |
XPO1 |
unspecified peripheral T-cell lymphoma |
missense_variant |
5.263% (1/19) |
1 entry |
ENSG00000082898 |
XPO1 |
angioimmunoblastic T-cell lymphoma |
missense_variant |
0.9346% (1/107) |
1 entry |
ENSG00000082898 |
XPO1 |
endometrial carcinoma |
missense_variant |
3.704% (1/27) |
1 entry |
ENSG00000082898 |
XPO1 |
head and neck squamous cell carcinoma |
missense_variant |
0.159% (1/629) |
1 entry |
ENSG00000082898 |
XPO1 |
adenosquamous lung carcinoma |
missense_variant |
4.545% (1/22) |
1 entry |
ENSG00000082898 |
XPO1 |
Brain Stem Glioblastoma |
frameshift_variant |
3.571% (2/56) |
1 entry |
ENSG00000082898 |
XPO1 |
melanoma |
sequence_alteration |
2.759% (4/145) |
1 entry |